<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03550911</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0014</org_study_id>
    <nct_id>NCT03550911</nct_id>
  </id_info>
  <brief_title>Biological Collection From Samples From The Gut Microbiota In Patients Having A Bone Or Joint Infection Treated By A Suppressive Subcutaneous Antibiotherapy With Betalactamine (CARBAMICROBIOTA)</brief_title>
  <official_title>Constitution Of A Biological Collection From Samples From The Gut Microbiota In Patients Having A Bone Or Joint Infection Treated By A Suppressive Subcutaneous Antibiotherapy With Betalactamine (CARBAMICROBIOTA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Optimal surgical therapy (debridement in chronic osteomyelitis; device exchange in patients
      with chronic prosthetic joint infection (PJI)) could be sometimes non-feasible, especially in
      the elderly population. Therefore, a medical therapy with oral prolonged suppressive
      antibiotic therapy (PSAT) seems to be an option to prevent recurrence and prosthesis
      loosening. Unfortunately, some patients are infected with resistant pathogens for which oral
      antibiotics are not suitable. Subcutaneous (SC) administration of injectable intravenous
      antibiotics as prolonged suppressive antibiotic therapy could be a convenient way to limit
      catheter-related complications and facilitate ambulatory care.

      However, there are few data concerning the development of resistance under subcutaneous
      prolonged treatment with betalactamine.

      The aim of this study is just to constitute a biological collection from samples from the Gut
      microbiota in patients having a bone or joint infection treated by a suppressive subcutaneous
      antibiotherapy with betalactamine. Later analysis will be led on those samples to detect the
      acquisition of resistance or not.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2018</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biological Collection From Samples From The Gut Microbiota</measure>
    <time_frame>1 day</time_frame>
    <description>The aim of this study is just to constitute a biological collection from samples from the Gut microbiota in patients having a bone or joint infection treated by a suppressive subcutaneous antibiotherapy with betalactamine.
No analysis will be done for instance.</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Bone Infection</condition>
  <condition>Joint Infection</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological Collection From Samples From The Gut Microbiota</intervention_name>
    <description>The aim of this study is just to constitute a biological collection from samples from the Gut microbiota in patients having a bone or joint infection treated by a suppressive subcutaneous antibiotherapy with betalactamine. No analysis will be done for instance.</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biological collection from samples from the GUT microbiota in patients having a bone or joint
      infection treated by a suppressive subcutaneous antibiotherapy with betalactamine. No
      analysis will be done for instance.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients having a bone or joint infection treated by a suppressive subcutaneous
        antibiotherapy with betalactamine.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients having a bone or joint infection

          -  Patients treated by a suppressive subcutaneous antibiotherapy with betalactamine

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tristan FERRY, MD, PhD</last_name>
    <phone>04 72 07 11 07</phone>
    <phone_ext>+33</phone_ext>
    <email>tristan.ferry@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eugénie MABRUT</last_name>
    <phone>04 26 73 29 38</phone>
    <phone_ext>+33</phone_ext>
    <email>eugenie.mabrut@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de référence des infections ostéo-articulaires de Lyon - Hôpital de la Croix-Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tristan FERRY, MD, PhD</last_name>
      <phone>04 72 07 11 07</phone>
      <phone_ext>+33</phone_ext>
      <email>tristan.ferry@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Eugénie MABRUT</last_name>
      <phone>04 26 73 29 38</phone>
      <phone_ext>+33</phone_ext>
      <email>eugenie.mabrut@chu-lyon.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 28, 2018</study_first_submitted>
  <study_first_submitted_qc>May 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2018</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Arthritis, Infectious</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

